Stock detail

Türk İlaç ve Serum Sanayi A.Ş.

TRILCSTOCKS | TR | IST | Healthcare | Drug Manufacturers - Specialty & Generic

Profile snapshotTRY 0.8Market cap TRY 798.5M

No local candle data found.

Recent detected patterns / setups

Latest 10 Market Radar results for this symbol and selected direction.

PatternTFScan runQuality

BullishOliver Kell Momentum Setup15M07 Nov 26, 09:1479

BullishICT Inverse FVG Setup15M07 Nov 26, 09:1486

BullishICT FVG Setup15M07 Nov 26, 09:14100

BullishOliver Kell Momentum Setup4H06 Nov 26, 16:1777

BullishICT FVG Reaction Setup4H + 15M06 Nov 26, 16:1792

BearishICT Inverse FVG Setup4H06 Nov 26, 16:1797

BullishICT FVG Setup4H06 Nov 26, 16:17100

BearishICT FVG Reaction Setup1D + 15M06 Nov 26, 16:1797

BullishICT Inverse FVG Setup1D06 Nov 26, 16:17100

BullishICT FVG Setup1D06 Nov 26, 16:17100

About Türk İlaç ve Serum Sanayi A.Ş.

Türk İlaç ve Serum Sanayi A.Ş. (TRILC) is listed on IST. Sector: Healthcare. Industry: Drug Manufacturers - Specialty & Generic.

Turk Ilac Ve Serum Sanayi Anonim Sirketi produces and sells human tablets, capsules, ampoules, vials, ointments-creams, intravenous serums, parenteral solutions, nutritional solutions, amino acids, and other chemicals in Turkey. It also offers bulb, biological, and serum products, as well as medical devices. Turk Ilac Ve Serum Sanayi Anonim Sirketi was founded in 2010 and is headquartered in Ankara, Turkey.

Annual

Annual fundamentals

2025 vs previous annual period

Total revenueTRY 4.5B+35.3%

Net incomeTRY -622.6M-757.4%

Net profit margin-13.7%-16.5 pp

EPS-0.6-752.5%

Total debtTRY 3.4B+56.5%

Cash and cash equivalentsTRY 11.3M+24.9%

Net debtTRY 3.4B+56.7%

Metric20212022202320242025

Total revenueTRY 672.6M--TRY 1.6B+143.4%TRY 2.8B+69.5%TRY 3.4B+20.9%TRY 4.5B+35.3%

Net incomeTRY 37.1M--TRY -81.7M-319.9%TRY 152.6M+286.9%TRY 94.7M-37.9%TRY -622.6M-757.4%

Net profit margin5.5%---5.0%-190.3%5.5%+210.3%2.8%-48.7%-13.7%-585.9%

EPS0.04---0.08-319.6%0.15+286.1%0.09-37.2%-0.6-752.5%

Free cash flowTRY -92.3M--TRY 109.5M+218.7%TRY 292.9M+167.4%TRY -688.6M-335.1%TRY 357.8M+152.0%

Total debtTRY 197.2M--TRY 511.7M+159.4%TRY 619.8M+21.1%TRY 2.2B+248.3%TRY 3.4B+56.5%

Cash and cash equivalentsTRY 44.8M--TRY 10M-77.6%TRY 8.1M-19.4%TRY 9M+12.0%TRY 11.3M+24.9%

Net debtTRY 152.4M--TRY 501.6M+229.1%TRY 611.7M+21.9%TRY 2.1B+251.5%TRY 3.4B+56.7%

Quarterly

Quarterly fundamentals

Q2 2026 vs same quarter previous year

Total revenueTRY 1.5B+10.1%

Net incomeTRY -105.8M-151.0%

Net profit margin-6.9%-21.9 pp

EPS----

Total debtTRY 4.3B+4.2%

Cash and cash equivalentsTRY 15.7M-65.3%

Net debtTRY 4.3B+5.0%

MetricQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Total revenue----TRY 732M--TRY 1.2B--TRY 1.8B+110.0%TRY 1.4B--TRY 1.5B+108.9%

Net income----TRY -251.9M--TRY 119M--TRY -128M-3850.4%TRY 207.6M--TRY -105.8M+58.0%

Net profit margin-----34.4%--10.2%---6.9%-1885.6%14.9%---6.9%+79.9%

EPS-0.38---0.24--0.12------0.2+152.7%----

Free cash flow----TRY -479.7M--TRY 635.9M--TRY 208.9M+88.7%TRY -737.2M--TRY -114.1M+76.2%

Total debt----TRY 2.3B--TRY 2.7B--TRY 3.4B+104.9%TRY 4.1B--TRY 4.3B+88.9%

Cash and cash equivalents----TRY 17.7M--TRY 12.4M--TRY 11.3M+63.4%TRY 45.1M--TRY 15.7M-11.4%

Net debt----TRY 2.3B--TRY 2.7B--TRY 3.4B+105.1%TRY 4.1B--TRY 4.3B+89.7%

Ownership

Institutional ownership summary

2026 Q3, quarter ended 2026-08-21

PeriodOwnershipInstitutions13F sharesTotal investedPositions